On August 30th, an investor asked Jinjia Biopharmaceutical Technology Co., Ltd. (002191.SZ) on the investor communication platform Equity Easylive: "May I ask, for what reasons did the company choose to expand its market presence to the United States?
In response, Jinjia Corporation stated that the company is advancing its new tobacco business in accordance with market conditions and relevant policies. In the overseas e-cigarette market, the company is focusing on expanding its vape business in European and American markets such as the UK, Germany, and the US, while its overseas subsidiaries are prioritizing the development of heated tobacco products in markets in Southeast Asia, the Middle East, and Japan.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
